88results about "Integrin superfamily" patented technology

Described herein are muscle-specific targeting moieties and compositions including the muscle specific targeting motifs. Also described herein are uses of the muscle-specific targeting motifs and compositions including the muscle specific targeting moieties. In some embodiments, the muscle-specific targeting moieties and compositions including the muscle specific targeting moieties can be used to direct delivery of a cargo to a muscle cell.

Described herein are compounds having affinity for integrins, the synthesis of these compounds, and the use of these compounds as ligands to facilitate the delivery of cargo molecules to cells expressing integrins. The described integrin-targeting ligands have serum stability and affinity for αvβ3 integrin and / or αvβ5 integrin, and are suitable for conjugation to cargo molecules, such as oligonucleotide-based therapeutic agents (e.g., RNAi agents), to facilitate the delivery of cargo molecules to cells or tissues expressing integrin αvβ3, integrin αvβ5, or both integrin αvβ3 and integrin αvβ5, such as tumor cells. Compositions and methods of use containing the integrin-targeting ligands are also described.

Provided herein are compounds that inhibit a binding interaction between a β integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.

Provided are compositions comprising: a first polypeptide comprising a first fragment of an extracellular domain of ITGA2B or ITGB3, or an analog or derivative thereof, and a dimerization domain; and a second polypeptide comprising a second fragment of the extracellular domain of ITGA2B or ITGB3, or an analog or derivative thereof, and a dimerization domain. Also provided are polypeptides comprising a fragment of an extracellular domain of ITGA2B or ITGB3. Also provided is a pharmaceutical composition comprising the composition, a polypeptide; nucleic acid systems and molecules encoding the polypeptides of the compositions of the invention; and methods of treating and determining therapeutic suitability using the compositions or polypeptides; and methods of producing the compositions or proteins.

The present invention resides in the discovery that the specific interaction between vascular endothelial growth factor (VEGF) and integrin, especially integrin αvβ3, is involved in cellular signaling mediated by VEGF-integrin, such as angiogenesis and inflammatory responses. Thus, this invention provides for a novel method for inhibiting angiogenesis or inflammation induced by integrin signaling by using an inhibitor of VEGF-integrin binding, such as a dominant negative mutant of VEGF without integrin-binding capability. A method for identifying inhibitors of VEGF-integrin binding is also described. Further disclosed are polypeptides, nucleic acids, host cells, and corresponding compositions for inhibiting VEGF-integrin signaling.

The present application concerns methods for detecting and isolating a population of neural stem cells (NSC) or neural progenitor cells (NPC) based on expression of the marker integrin alpha10beta1; as well as use of said population of NSC or NPC for therapy, diagnosis and prognosis of disease and damage of the CNS.

Provided is a protein substrate comprising an integrin-binding motif and a growth factor (GF)-binding peptide motif capable of simultaneously or selectively binding to or activating both growth factor receptors and integrins. The substrate protein may be in the form of a mussel adhesive protein, in which an extracellular matrix (ECM) protein and a GF-binding peptide motif derived from the integrin-binding peptide motif are recombinantly integrated into the mussel adhesive protein. Also provided is the use of the protein substrate to modulate cellular behavior, including cell attachment, migration, or proliferation, which are essential processes in biological processes, wound healing, tissue engineering, and therapeutic applications. In another embodiment, the present invention provides methods and compositions for stabilizing and protecting growth factors from protease digestion or internalization (or cellular uptake) into cells to maintain continuous and sustained function of the growth factors.

Provided herein are recombinant miniature swine without expression of endogenous porcine CD47 and SIRPA, but with the expression of human or humanized CD47 and human or humanized SIRPA under the same regulatory elements as the endogenous porcine CD47 and SIRPA. Also provided are cells, tissues, and organs derived from such recombinant miniature swine. Furthermore, provided herein are methods of transplanting a graft from a first donor of such recombinant miniature swine with or without bone marrow from a second donor of such recombinant miniature swine.

The invention provides a DC-activated chimeric antigen receptor, a vector, a gene engineering modified cell, a drug, a preparation method and application, and particularly belongs to the technical field of biological medicine. The DC activated chimeric antigen receptor sequentially comprises a signal peptide, an antigen binding structural domain, a hinge region, a transmembrane structural domain and an intracellular signal activation structural domain, the intracellular signal activation structural domain comprises one or more than two of TAC1, BAFFR, LRP1, OX40L, FcR gamma, DC-SIGN, TLR4, 4-1BB, CD40, CD86, DAP12, B7-H3, CD49a, BLAME, SLAMF4, MARCO, TLR7, CD103, CD54 and CD83. The invention further discloses a preparation method of the intracellular signal activation structural domain. The DC activated chimeric antigen receptor disclosed by the invention can enhance a DC activation signal, overcome microenvironment inhibition of solid tumors and realize immunotherapy of the solid tumors.

The present invention provides methods for preselecting TILs based on PD-1, CD39, CD38, CD103, CD101, LAG3, TIM3, and / or TIGIT expression, as well as methods for expanding those preselected PD-1, CD39, CD38, CD103, CD101, LAG3, TIM3, and / or TIGIT positive TILs to produce therapeutic TIL populations with enhanced tumor-specific killing capacity (e.g., enhanced cytotoxicity).

A composition is provided comprising a first polypeptide comprising a first fragment or analog or derivative of the extracellular domain of ITGA2B or ITGB3 and a dimerization domain, and a second polypeptide comprising a second fragment or analog or derivative of the extracellular domain of ITGA2B or ITGB3 and a dimerization domain. Polypeptides comprising fragments of the extracellular domain of ITGA2B or ITGB3 are also provided. Pharmaceutical compositions comprising the composition, polypeptide, nucleic acid system, and molecule encoding the polypeptide of the above composition are also provided, as well as therapeutic methods using the above composition or polypeptide, methods for determining suitability for therapeutic use of the above composition or polypeptide, and methods for producing the above composition or protein.

An immunosuppressive molecule comprising an immunosuppressive protein binding domain, a transmembrane domain and a co-stimulatory domain and the molecule does not comprise a primary signaling domain, wherein the immunosuppressive protein is selected from two or more of NKG2A, TIM3, LAG3, TIGIT, CTLA4, PD1 and FasL. An engineered cell expressing the immunosuppressive molecule and a composition comprising the engineered cell. A method for reducing immune rejection using the immunosuppressive molecule.

The present disclosure relates to an engineered hematopoietic cell comprising a very late antigen-4 (VLA-4) variant and uses thereof in treating an inherited genetic disorder or an acquired disorder.

Described herein are muscle-specific targeting moieties and compositions including the muscle specific targeting motifs. Also described herein are uses of the muscle-specific targeting motifs and compositions including the muscle specific targeting moieties. In some embodiments, the muscle-specific targeting moieties and compositions including the muscle specific targeting moieties can be used to direct delivery of a cargo to a muscle cell.

Provided herein are recombinant minipigs that do not express endogenous porcine CD47 and SIRPA, but express human or humanized CD47 and human or humanized SIRPA under the same regulatory elements as the endogenous porcine CD47 and SIRPA. Also provided are cells, tissues, and organs derived from such recombinant minipigs. Additionally provided herein are methods of transplanting grafts derived from such recombinant minipigs of a first donor with or without bone marrow derived from such recombinant minipigs of a second donor.

Provided herein are [alpha] 4 [beta] 1 / 7 integrin receptor ligand-containing compounds, methods of delivering the compounds, and methods of using the compounds to treat diseases, disorders, and symptoms (e.g., central nervous system diseases, disorders, and symptoms) in a subject.

Provided herein are α4β 1 / 7 Integrin receptor ligand-containing compounds, methods of delivering the compounds, and methods of using the compounds to treat diseases, disorders, and conditions in a subject (e.g., diseases, disorders, and conditions of the central nervous system). 1 / 7 The present invention relates to compounds (eg, any of those defined herein) and methods for targeting cells expressing integrin receptors (collectively referred to as "integrin receptors").

Provided herein are recombinant minipigs that do not express endogenous porcine CD47 and SIRPA, but express human or humanized CD47 and human or humanized SIRPA under the same regulatory elements as the endogenous porcine CD47 and SIRPA. Also provided are cells, tissues, and organs derived from such recombinant minipigs. Additionally provided herein are methods of transplanting grafts derived from such recombinant minipigs of a first donor with or without bone marrow derived from such recombinant minipigs of a second donor.

Compounds having affinity for integrins, the synthesis of these compounds, and the use of these compounds as ligands to facilitate the delivery of cargo molecules to cells expressing integrins are described. The described integrin targeting ligands have serum stability and affinity for αvβ3 integrin and / or αvβ5 integrin, and are suitable for conjugation to cargo molecules, such as such as oligonucleotide-based therapeutic agents (e.g., RNAi agents), to facilitate delivery of the cargo molecules to cells and tissues, such as tumor cells, that express integrin αvβ3, integrin αvβ5, or both integrin αvβ3 and integrin αvβ5. Compositions that include integrin targeting ligands and methods of use are also described.

The disclosure relates to integrin binding peptides, pharmaceutical compositions comprising the peptides and to uses thereof as therapeutic, diagnostic, imaging and targeting agents.

Provided relates to a circular RNA comprising an internal ribosome entry site (IRES) element, a protein coding sequence and a poly A. Provided also relates to the precursor RNA, the vector and the method for producing the circular, and the use of the circular RNA.

Aspects of the disclosure relate to compositions comprising populations of isolated amniotic cells. In some embodiments, the populations of cells are enriched for human amniotic epithelial cells (hAECs). In some embodiments, the disclosure provides methods of administering the compositions to a subject, for example a subject having certain diseases or disorders such as liver disease, phenylketonuria (PKU), a vocal cord injury or a disease associated with a Complement Factor H deficiency.

Provided are a tissue-specific promoter and use thereof. The tissue-specific promoter has a nucleic acid sequence comprising more than 80% of the sequence as shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4. The tissue-specific promoter can promote the specific expression of a coding gene in endothelial cells (ECs) or megakaryocyte-platelet cells and can be applied to gene therapy in which a gene is required to be specifically expressed in ECs or megakaryocyte-platelet cells, ensuring a therapeutic effect, reducing a risk of immune rejection and saving a therapeutic cost.

Modified integrin polypeptides are provided. Methods of identifying binding agents that bind to a modified integrin polypeptide are also provided.

To provide compounds having affinity for integrins, to provide the synthesis of these compounds, and to provide use of these compounds as ligands to facilitate the delivery of cargo molecules to cells expressing integrins.SOLUTION: Compounds having affinity for integrins, the synthesis of these compounds, and use of these compounds as ligands to facilitate the delivery of cargo molecules to cells expressing integrins are described. The described integrin targeting ligands have serum stability and affinity for αvβ3 integrin and / or αvβ5 integrin, and are suitable for conjugation to cargo molecules, such as oligonucleotide-based therapeutic agents (e.g., RNAi agents), to facilitate delivery of the cargo molecules to cells and tissues, such as tumor cells, that express integrin αvβ3, integrin αvβ5, or both integrin αvβ3 and integrin αvβ5. Compositions that include integrin targeting ligands and methods of use are also described.SELECTED DRAWING: None

The present disclosure provides an antibody fusion protein comprising: (i) a heavy chain comprising a variable region sequence comprising the amino acid sequence of SEQ ID NO: 1; and (ii) a light chain comprising a variable region sequence comprising the amino acid sequence of SEQ ID NO: 8, wherein the light chain is fused at its C-terminus to an A1-A2 domain comprising the amino acid sequence of SEQ ID NO: 11. Nucleic acids encoding all or a portion of the antibody fusion protein are provided, as well as methods of using the antibody fusion protein, e.g., in treating CD20-positive cancers. The present disclosure further provides mutant A1-A2 domain peptides.

Provided herein are recombinant miniature swine without expression of endogenous porcine CD47 and SIRPA, but with the expression of human or humanized CD47 and human or humanized SIRPA under the same regulatory elements as the endogenous porcine CD47 and SIRPA. Also provided are cells, tissues, and organs derived from such recombinant miniature swine. Furthermore, provided herein are methods of transplanting a graft from a first donor of such recombinant miniature swine with or without bone marrow from a second donor of such recombinant miniature swine.

The present disclosure deals with lipid nanoparticle (LNP) compositions ITB6 molecules and uses thereof. The LNP compositions of the present disclosure include mRNA therapeutics encoding ITB6 polypeptides. The LNP compositions of the present disclosure can reprogram dendritic cells, suppress T cells, and / or induce immune tolerance in vivo. Also disclosed herein are methods of using LNP compositions comprising polynucleotides (e.g., mRNA) encoding ITB6 molecules to treat diseases associated with abnormal T cell function or inhibit immune responses in a subject.